Evaluation of randomized discontinuation design

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 5094-5098

  Freidlin, Boris ^a   Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; PLACEBO; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DESIGN; GROWTH RATE; HUMAN; INTERMETHOD COMPARISON; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH; BIOASSAY; METHODOLOGY; NEOPLASM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 24644438754     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.520     Document Type: Article

References (22)

1. Balis FM: Evolution of anticancer drug discovery and the role of cell based screening. J Natl Cancer Inst 94:78-79, 2002
2. Schilsky RL: End points in cancer clinical trials and the drug approval process. Clin Cancer Res 8:935-938, 2002
3. Rothenberg ML, Carbone DP, Johnson DH: Improving the evaluation of new cancer treatments: Challenges and opportunities. Nat Rev Cancer 3:303-309, 2003
4. Johnson DH: Targeted therapy in non-small cell lung cancer: Myth or reality. Lung Cancer 41:s3-s8, 2003
5. Dancey JE, Freidlin B: Targeting epidermal growth factor receptor: Are we missing the mark? Lancet 362:62-64, 2003
6. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-2499, 2002
7. Stadler WM, Ratain MJ: Development of target-based antineoplastic agents. Invest New Drugs 18:7-16, 2000
8. Fox E, Curt GA, Balis FM: Clinical trial design for target-based therapy. Oncologist 7:401-409, 2002
9. Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. Ann Oncol 9:1047-1052, 1998
10. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
11. Millar AW, Lynch KP: Rethinking clinical trials for cytostatic drugs. Nat Rev Cancer 3:540-545, 2003
12. Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. Cancer Treat Rep 69:1375-1381, 1985
13. Buyse M: Randomized designs for early trials of new cancer treatments: An overview. Drug Inf J 34:387-396, 2000
14. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-4484, 2002
15. Temple RJ: Special study designs: Early escape, enrichment, studies in non-responders. Commun Statist-Theory Meth 23:499-531, 1994
16. Nottage M, Siu LL: Principles of clinical trial design. J Clin Oncol 20:42s-46s, 2002 (suppl)
17. Capra WB: Comparing the power of the randomized discontinuation design to that of the classic randomized design on time-to-event endpoints. Control Clin Trials 25:168-177, 2004
18. Ratain MJ, Stadler WM: Clinical trials designs for cytostatic agents. J Clin Oncol 19:3154, 2001
19. Yang JC, Haworth L, Sherry RM: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
20. Leber PD, Davis CS: Threats to validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 19:178-187, 1998
21. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trials designs for cytostatic agents. J Clin Oncol 19:3154-3155, 2001
22. Freidlin B, Korn EL: A testing procedure for survival data with few responders. Stat Med 21:65-78, 2002